Lit Matters 1: Is Phenobarb Better Than Benzos for Alcohol Withdrawal?

Alcohol withdrawal syndrome in the ED is still a benzodiazepine-first problem, but phenobarbital remains a credible alternative when CIWA drugs are scarce or dysautonomia dominates. Current ED-focused evidence suggests similar safety and disposition outcomes rather than clear superiority for either strategy.

Phenobarbital vs Benzodiazepines in AWS

• Bottom-line equivalence signal: Meta-analyzed ED data did not show phenobarbital reducing ICU admission, hospital admission, ED return, or adverse events compared with benzodiazepines alone.
• Evidence quality limitations: Only eight studies met inclusion, with just two prospective RCTs, and bias plus confounding were substantial enough that utilization outcomes deserve cautious interpretation.
• Safety profile comparison: Across the pooled literature, no deaths were reported and nonfatal events like seizures, hypotension, and respiratory suppression were broadly similar between treatment groups.
• Sedative burden difference: Patients receiving any phenobarbital generally accumulated more total sedative-hypnotic exposure, about 30.7 lorazepam equivalents versus 10.7 with benzodiazepines alone.
• Phenobarbital practical niche: Phenobarbital is a reasonable ED option when benzodiazepines are limited, especially for prominent dysautonomia, and its long half-life and oral route matter in real practice. We get into where monotherapy fits in the episode.